{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:43:02Z","timestamp":1791474182294,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970750"],"award-info":[{"award-number":["81970750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["YXMJ-QN-01"],"award-info":[{"award-number":["YXMJ-QN-01"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clnu.2024.06.018","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T11:46:03Z","timestamp":1718797563000},"page":"1769-1780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4"],"prefix":"10.1016","volume":"43","author":[{"given":"Mingfeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruike","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohe","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5739-4376","authenticated-orcid":false,"given":"Yanli","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2024.06.018_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41574-022-00711-5","article-title":"Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation","volume":"18","author":"Lonardo","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clnu.2024.06.018_bib2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2024.06.018_bib3","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clnu.2024.06.018_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clnu.2024.06.018_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/nu13020599","article-title":"Epigallocatechin-3-Gallate dampens non-alcoholic fatty liver by modulating liver function, lipid profile and macrophage polarization","volume":"13","author":"Du","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.06.018_bib6","doi-asserted-by":"crossref","first-page":"9924","DOI":"10.1039\/D0FO02152K","article-title":"Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet","volume":"11","author":"Huang","year":"2020","journal-title":"Food Funct"},{"key":"10.1016\/j.clnu.2024.06.018_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1148814","article-title":"Epigallocatechin gallate alleviates high-fat diet-induced hepatic lipotoxicity by targeting mitochondrial ROS-mediated ferroptosis","volume":"14","author":"Ding","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clnu.2024.06.018_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/nu15133022","article-title":"Therapeutic activity of green tea epigallocatechin-3-gallate on metabolic diseases and non-alcoholic fatty liver diseases: the current updates","volume":"15","author":"James","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.06.018_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.02.015","article-title":"CD26\/DPP4 - a potential biomarker and target for cancer therapy","volume":"198","author":"Enz","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clnu.2024.06.018_bib10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/alz.12437","article-title":"Nonenzymatic function of DPP4 in diabetes-associated mitochondrial dysfunction and cognitive impairment","volume":"18","author":"Sun","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.clnu.2024.06.018_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcmgh.2018.08.008","article-title":"Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice","volume":"7","author":"Nishina","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2024.06.018_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40618-020-01392-5","article-title":"Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD\/NASH in individuals with and without obesity and metabolic disease","volume":"44","author":"Barchetta","year":"2021","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.clnu.2024.06.018_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101806","article-title":"Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy","volume":"78","author":"Song","year":"2023","journal-title":"Mol Metabol"},{"key":"10.1016\/j.clnu.2024.06.018_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154314","article-title":"Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression","volume":"8","author":"Trzaskalski","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.clnu.2024.06.018_bib15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.molmet.2017.07.016","article-title":"Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease","volume":"6","author":"Baumeier","year":"2017","journal-title":"Mol Metabol"},{"key":"10.1016\/j.clnu.2024.06.018_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5370759","article-title":"Dipeptidyl peptidase-4 is a target protein of epigallocatechin-3-gallate","volume":"2020","author":"Hou","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.clnu.2024.06.018_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1017\/S0007114513003784","article-title":"Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial","volume":"111","author":"Mielgo-Ayuso","year":"2014","journal-title":"Br J Nutr"},{"key":"10.1016\/j.clnu.2024.06.018_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jff.2014.04.010","article-title":"Effects of green tea catechins on nonalcoholic steatohepatitis (NASH) patients","volume":"9","author":"Fukuzawa","year":"2014","journal-title":"J\u00a0Funct Foods"},{"key":"10.1016\/j.clnu.2024.06.018_bib19","series-title":"Announcement on approval of new resource foods such as rhodococcus pluvialis (No. 17 of 2010)","year":"2010"},{"key":"10.1016\/j.clnu.2024.06.018_bib20","first-page":"1677","article-title":"The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice","volume":"138","author":"Bose","year":"2008","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.clnu.2024.06.018_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/mnfr.201300335","article-title":"Epigallocatechin gallate improves insulin signaling by decreasing toll-like receptor 4 (TLR4) activity in adipose tissues of high-fat diet rats","volume":"58","author":"Bao","year":"2014","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.clnu.2024.06.018_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/nu12051316","article-title":"Beyond body weight-loss: dietary strategies targeting intrahepatic fat in NAFLD","volume":"12","author":"Worm","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.06.018_bib23","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2024.06.018_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","article-title":"Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD","volume":"18","author":"Tamaki","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clnu.2024.06.018_bib25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clnu.2015.05.003","article-title":"Therapeutic effect of high-dose green tea extract on weight reduction: a randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Chen","year":"2016","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnu.2024.06.018_bib26","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3945\/ajcn.116.137075","article-title":"Effects of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial","volume":"104","author":"Samavat","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2024.06.018_bib27","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1210\/clinem\/dgab078","article-title":"DPP4 activity, hyperinsulinemia, and atherosclerosis","volume":"106","author":"Love","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clnu.2024.06.018_bib28","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db10-1338","article-title":"Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice","volume":"60","author":"Shirakawa","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clnu.2024.06.018_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.diabres.2014.04.028","article-title":"Sitagliptin attenuates methionine\/choline-deficient diet-induced steatohepatitis","volume":"105","author":"Jung","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clnu.2024.06.018_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3892\/ijmm.2017.2899","article-title":"A\u00a0long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob\/ob mice","volume":"39","author":"Nakamura","year":"2017","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.clnu.2024.06.018_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000491763","article-title":"Effects of a DPP4 inhibitor on progression of NASH-related HCC and the p62\/Keap1\/Nrf2-Pentose phosphate pathway in a mouse model","volume":"8","author":"Kawaguchi","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.clnu.2024.06.018_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109173","article-title":"Green tea extract exhibits antidiabetic effects partly through regulating dipeptidyl peptidase-4 expression in adipose tissue","volume":"111","author":"Choi","year":"2023","journal-title":"J\u00a0Nutr Biochem"},{"key":"10.1016\/j.clnu.2024.06.018_bib33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA Carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2024.06.018_bib34","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","article-title":"An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease","volume":"78","author":"Lee","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clnu.2024.06.018_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jep.2017.08.035","article-title":"Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases","volume":"210","author":"Eng","year":"2018","journal-title":"J\u00a0Ethnopharmacol"},{"key":"10.1016\/j.clnu.2024.06.018_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154999","article-title":"EGCG attenuated acute myocardial infarction by inhibiting ferroptosis via miR-450b-5p\/ACSL4 axis","volume":"119","author":"Yu","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.clnu.2024.06.018_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40168-021-01115-9","article-title":"Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis","volume":"9","author":"Wu","year":"2021","journal-title":"Microbiome"},{"key":"10.1016\/j.clnu.2024.06.018_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canlet.2013.08.031","article-title":"Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions","volume":"342","author":"Kochi","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clnu.2024.06.018_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/aps.2015.11","article-title":"Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice","volume":"36","author":"Gan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clnu.2024.06.018_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2020.108455","article-title":"Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota","volume":"84","author":"Dey","year":"2020","journal-title":"J\u00a0Nutr Biochem"},{"key":"10.1016\/j.clnu.2024.06.018_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.961231","article-title":"Exercise inhibits JNK pathway activation and lipotoxicity via macrophage migration inhibitory factor in nonalcoholic fatty liver disease","volume":"13","author":"Cui","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2024.06.018_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120949","article-title":"Rhodiola activates macrophage migration inhibitory factor to alleviate non-alcoholic fatty liver disease","volume":"308","author":"Liu","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.clnu.2024.06.018_bib43","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1096\/fj.14-256776","article-title":"Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis","volume":"28","author":"Heinrichs","year":"2014","journal-title":"Faseb J"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424002115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424002115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:11:38Z","timestamp":1778505098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561424002115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0261561424002115"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2024.06.018","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2024.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}